Belpointe Asset Management LLC purchased a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 14,000 shares of the medical instruments supplier’s stock, valued at approximately $315,000.

Other large investors also recently bought and sold shares of the company. Alps Advisors Inc. increased its position in shares of OraSure Technologies by 0.3% in the second quarter. Alps Advisors Inc. now owns 43,257 shares of the medical instruments supplier’s stock worth $747,000 after acquiring an additional 111 shares in the last quarter. Profund Advisors LLC increased its position in shares of OraSure Technologies by 2.8% in the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 293 shares in the last quarter. Timber Hill LLC increased its position in shares of OraSure Technologies by 3.2% in the second quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock worth $200,000 after acquiring an additional 363 shares in the last quarter. Arizona State Retirement System increased its position in shares of OraSure Technologies by 3.4% in the second quarter. Arizona State Retirement System now owns 30,100 shares of the medical instruments supplier’s stock worth $520,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of OraSure Technologies by 17.6% in the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,360 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors.

In other news, Director Mara G. Aspinall purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, with a total value of $71,150.00. Following the acquisition, the director now owns 5,000 shares in the company, valued at $71,150. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) opened at $18.19 on Friday. The firm has a market cap of $1,103.19, a price-to-earnings ratio of 34.98, a P/E/G ratio of 3.49 and a beta of 1.28. OraSure Technologies, Inc. has a fifty-two week low of $8.39 and a fifty-two week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue was up 31.0% on a year-over-year basis. During the same period last year, the business earned $0.11 EPS. research analysts predict that OraSure Technologies, Inc. will post 0.42 EPS for the current year.

Several equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, September 20th. Jefferies Group lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of OraSure Technologies in a research report on Tuesday, September 19th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $18.21.

TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/17/belpointe-asset-management-llc-takes-position-in-orasure-technologies-inc-osur.html.

OraSure Technologies Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.